. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003 Apr 3;348(14) PubMed.

Recommends

Please login to recommend the paper.

Comments

Make a Comment

To make a comment you must login or register.

Comments on this content

  1. Any glutamate excess in Alzheimer's may be of glial origin. Aldehydic products of lipid peroxidation apparently inactivate glial glutamate uptake transporters. The correct approach to the problem is at a primary level, by correcting the lipid peroxidation with vitamin E, a measure which renders memantine trials completely unnecessary. Long-chain n-3 EFA are also recommended, to replace the marked oxidative loss of these vital synaptic membrane lipids seen in moderate to advanced disease. Primary prevention of the disease itself will first take place in Australia, where the National Institute of Good Health has plans to produce the world's first vitamin E-replete canola oil on a large scale. No mother using such oil in pregnancy will bear an ADHD child, and neither parent will develop Vegetable Oil Syndrome and eventual fullblown AD.

    References:
    Peers RJ (1993) Alzheimer's Disease and Vegetable Oils. NZ Med J, 106;481

This paper appears in the following:

News

  1. Memantine Relieves Symptoms in Moderate to Severe AD

Webinars

  1. Memantine: Implications for Treating Alzheimer's